Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma

Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic RCC (mRCC) is stil...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiezhao, Xu, Peng, Wang, Chongshan, Xu, Naijin, Xu, Abai, Xu, Yawen, Sadahira, Takuya, Araki, Motoo, Wada, Koichiro, Matsuura, Eiji, Watanabe, Masami, Zheng, Junxia, Sun, Pinghua, Huang, Peng, Nasu, Yasutomo, Liu, Chunxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400575/
https://www.ncbi.nlm.nih.gov/pubmed/28416753
http://dx.doi.org/10.18632/oncotarget.15505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400575/
https://www.ncbi.nlm.nih.gov/pubmed/28416753
http://dx.doi.org/10.18632/oncotarget.15505

Ejemplares similares